抗悪性腫瘍療法の世界市場成長(現状と展望)2024-2030年Global Anti-Neoplastic Therapy Market Growth (Status and Outlook) 2024-2030 LPI(LPインフォメーション)の最新調査によると、世界の抗新生物療法市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、抗新生物療法は2030年までに100万米ドルの再調整規模になる... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーLPI(LPインフォメーション)の最新調査によると、世界の抗新生物療法市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、抗新生物療法は2030年までに100万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは%である。この調査レポートは、世界の抗新生物療法市場の成長可能性を明らかにしています。抗新生物療法は今後の市場でも安定した成長が期待される。しかし、抗新生物療法の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場参入企業は、抗新生物療法市場が提供する膨大な機会を活用するために、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供を行う必要がある。 抗新生物療法とは、新生物の発生を予防、抑制、阻止することを目的とした療法を指す。 世界の医薬品市場は、2022年には1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 主な特徴 抗新生物療法市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。 市場規模と成長:この調査レポートは、抗新生物療法市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(例:化学療法剤、免疫療法剤)、地域別内訳などが含まれます。 市場促進要因と課題:政府規制、環境問題、技術進歩、消費者嗜好の変化など、抗悪性腫瘍剤市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も明らかにすることができる。 競合情勢:この調査レポートは、抗悪性腫瘍療法市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。 技術開発:調査レポートは、抗新生物療法業界における最新の技術開発について掘り下げることができます。これには、抗新生物療法技術の進歩、抗新生物療法新規参入企業、抗新生物療法新規投資、抗新生物療法の将来を形作るその他の技術革新が含まれる。 川下企業の好み:本レポートは、抗悪性腫瘍剤市場における顧客の購買行動や採用動向を明らかにします。このレポートには、顧客の購買決定や抗悪性腫瘍療法製品の嗜好に影響を与える要因が含まれています。 政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが抗新生物療法市場に与える影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、および抗新生物療法市場の促進を目的としたその他の措置の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価する。 環境への影響と持続可能性調査レポートは、抗新生物療法市場の環境影響と持続可能性の側面を評価します。 市場予測と将来展望:実施した分析に基づき、調査レポートは抗新生物療法産業の市場予測と展望を提供します。これには、市場規模、成長率、地域別動向、技術進歩や政策展開に関する予測などが含まれます。 提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、抗新生物療法市場の成長と発展に貢献するための潜在的な機会を強調しています。 市場の細分化 抗新生物療法市場はタイプ別と用途別に分類される。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を提供します。 タイプ別セグメント 化学療法剤 免疫治療薬 個別化医療 用途別セグメント 病院 診療所 癌リハビリセンター 外来手術センター 本レポートではまた、市場を地域別に分けています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 アムジェン社 アストラゼネカ バイエル ジョンソン・エンド・ジョンソン メルク・アンド・カンパニー ファイザー F.ホフマン・ラ・ロシュ社 イーライリリー・アンド・カンパニー テバ・ファーマシューティカル・インダストリーズ社 ベーリンガーインゲルハイム アスペン・ファーマケア・ホールディングス アッヴィ 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Anti-Neoplastic Therapy Market Size 2019-2030 2.1.2 Anti-Neoplastic Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Anti-Neoplastic Therapy Segment by Type 2.2.1 Chemotherapeutic Agents 2.2.2 Immunotherapeutic Agents 2.2.3 Personalized Medicine 2.3 Anti-Neoplastic Therapy Market Size by Type 2.3.1 Anti-Neoplastic Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Anti-Neoplastic Therapy Market Size Market Share by Type (2019-2024) 2.4 Anti-Neoplastic Therapy Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.4.3 Cancer Rehabilitation Centers 2.4.4 Ambulatory Surgical Centers 2.5 Anti-Neoplastic Therapy Market Size by Application 2.5.1 Anti-Neoplastic Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Anti-Neoplastic Therapy Market Size Market Share by Application (2019-2024) 3 Anti-Neoplastic Therapy Market Size by Player 3.1 Anti-Neoplastic Therapy Market Size Market Share by Players 3.1.1 Global Anti-Neoplastic Therapy Revenue by Players (2019-2024) 3.1.2 Global Anti-Neoplastic Therapy Revenue Market Share by Players (2019-2024) 3.2 Global Anti-Neoplastic Therapy Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Anti-Neoplastic Therapy by Regions 4.1 Anti-Neoplastic Therapy Market Size by Regions (2019-2024) 4.2 Americas Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.3 APAC Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.4 Europe Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.5 Middle East & Africa Anti-Neoplastic Therapy Market Size Growth (2019-2024) 5 Americas 5.1 Americas Anti-Neoplastic Therapy Market Size by Country (2019-2024) 5.2 Americas Anti-Neoplastic Therapy Market Size by Type (2019-2024) 5.3 Americas Anti-Neoplastic Therapy Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Anti-Neoplastic Therapy Market Size by Region (2019-2024) 6.2 APAC Anti-Neoplastic Therapy Market Size by Type (2019-2024) 6.3 APAC Anti-Neoplastic Therapy Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Anti-Neoplastic Therapy by Country (2019-2024) 7.2 Europe Anti-Neoplastic Therapy Market Size by Type (2019-2024) 7.3 Europe Anti-Neoplastic Therapy Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Anti-Neoplastic Therapy by Region (2019-2024) 8.2 Middle East & Africa Anti-Neoplastic Therapy Market Size by Type (2019-2024) 8.3 Middle East & Africa Anti-Neoplastic Therapy Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Anti-Neoplastic Therapy Market Forecast 10.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030) 10.1.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030) 10.1.2 Americas Anti-Neoplastic Therapy Forecast 10.1.3 APAC Anti-Neoplastic Therapy Forecast 10.1.4 Europe Anti-Neoplastic Therapy Forecast 10.1.5 Middle East & Africa Anti-Neoplastic Therapy Forecast 10.2 Americas Anti-Neoplastic Therapy Forecast by Country (2025-2030) 10.2.1 United States Anti-Neoplastic Therapy Market Forecast 10.2.2 Canada Anti-Neoplastic Therapy Market Forecast 10.2.3 Mexico Anti-Neoplastic Therapy Market Forecast 10.2.4 Brazil Anti-Neoplastic Therapy Market Forecast 10.3 APAC Anti-Neoplastic Therapy Forecast by Region (2025-2030) 10.3.1 China Anti-Neoplastic Therapy Market Forecast 10.3.2 Japan Anti-Neoplastic Therapy Market Forecast 10.3.3 Korea Anti-Neoplastic Therapy Market Forecast 10.3.4 Southeast Asia Anti-Neoplastic Therapy Market Forecast 10.3.5 India Anti-Neoplastic Therapy Market Forecast 10.3.6 Australia Anti-Neoplastic Therapy Market Forecast 10.4 Europe Anti-Neoplastic Therapy Forecast by Country (2025-2030) 10.4.1 Germany Anti-Neoplastic Therapy Market Forecast 10.4.2 France Anti-Neoplastic Therapy Market Forecast 10.4.3 UK Anti-Neoplastic Therapy Market Forecast 10.4.4 Italy Anti-Neoplastic Therapy Market Forecast 10.4.5 Russia Anti-Neoplastic Therapy Market Forecast 10.5 Middle East & Africa Anti-Neoplastic Therapy Forecast by Region (2025-2030) 10.5.1 Egypt Anti-Neoplastic Therapy Market Forecast 10.5.2 South Africa Anti-Neoplastic Therapy Market Forecast 10.5.3 Israel Anti-Neoplastic Therapy Market Forecast 10.5.4 Turkey Anti-Neoplastic Therapy Market Forecast 10.5.5 GCC Countries Anti-Neoplastic Therapy Market Forecast 10.6 Global Anti-Neoplastic Therapy Forecast by Type (2025-2030) 10.7 Global Anti-Neoplastic Therapy Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Amgen Inc. 11.1.1 Amgen Inc. Company Information 11.1.2 Amgen Inc. Anti-Neoplastic Therapy Product Offered 11.1.3 Amgen Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Amgen Inc. Main Business Overview 11.1.5 Amgen Inc. Latest Developments 11.2 AstraZeneca plc 11.2.1 AstraZeneca plc Company Information 11.2.2 AstraZeneca plc Anti-Neoplastic Therapy Product Offered 11.2.3 AstraZeneca plc Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 AstraZeneca plc Main Business Overview 11.2.5 AstraZeneca plc Latest Developments 11.3 Bayer AG 11.3.1 Bayer AG Company Information 11.3.2 Bayer AG Anti-Neoplastic Therapy Product Offered 11.3.3 Bayer AG Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Bayer AG Main Business Overview 11.3.5 Bayer AG Latest Developments 11.4 Johnson & Johnson 11.4.1 Johnson & Johnson Company Information 11.4.2 Johnson & Johnson Anti-Neoplastic Therapy Product Offered 11.4.3 Johnson & Johnson Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Johnson & Johnson Main Business Overview 11.4.5 Johnson & Johnson Latest Developments 11.5 Merck & Co., Inc. 11.5.1 Merck & Co., Inc. Company Information 11.5.2 Merck & Co., Inc. Anti-Neoplastic Therapy Product Offered 11.5.3 Merck & Co., Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Merck & Co., Inc. Main Business Overview 11.5.5 Merck & Co., Inc. Latest Developments 11.6 Pfizer Inc. 11.6.1 Pfizer Inc. Company Information 11.6.2 Pfizer Inc. Anti-Neoplastic Therapy Product Offered 11.6.3 Pfizer Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 Pfizer Inc. Main Business Overview 11.6.5 Pfizer Inc. Latest Developments 11.7 F. Hoffmann-La Roche Ltd. 11.7.1 F. Hoffmann-La Roche Ltd. Company Information 11.7.2 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Product Offered 11.7.3 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 F. Hoffmann-La Roche Ltd. Main Business Overview 11.7.5 F. Hoffmann-La Roche Ltd. Latest Developments 11.8 Eli Lilly and Company 11.8.1 Eli Lilly and Company Company Information 11.8.2 Eli Lilly and Company Anti-Neoplastic Therapy Product Offered 11.8.3 Eli Lilly and Company Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Eli Lilly and Company Main Business Overview 11.8.5 Eli Lilly and Company Latest Developments 11.9 Teva Pharmaceutical Industries Ltd. 11.9.1 Teva Pharmaceutical Industries Ltd. Company Information 11.9.2 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Product Offered 11.9.3 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 Teva Pharmaceutical Industries Ltd. Main Business Overview 11.9.5 Teva Pharmaceutical Industries Ltd. Latest Developments 11.10 Boehringer Ingelheim 11.10.1 Boehringer Ingelheim Company Information 11.10.2 Boehringer Ingelheim Anti-Neoplastic Therapy Product Offered 11.10.3 Boehringer Ingelheim Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.10.4 Boehringer Ingelheim Main Business Overview 11.10.5 Boehringer Ingelheim Latest Developments 11.11 Aspen Pharmacare Holdings Limited 11.11.1 Aspen Pharmacare Holdings Limited Company Information 11.11.2 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Product Offered 11.11.3 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.11.4 Aspen Pharmacare Holdings Limited Main Business Overview 11.11.5 Aspen Pharmacare Holdings Limited Latest Developments 11.12 AbbVie Inc. 11.12.1 AbbVie Inc. Company Information 11.12.2 AbbVie Inc. Anti-Neoplastic Therapy Product Offered 11.12.3 AbbVie Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.12.4 AbbVie Inc. Main Business Overview 11.12.5 AbbVie Inc. Latest Developments 12 Research Findings and Conclusion
SummaryAccording to our LPI (LP Information) latest study, the global Anti-Neoplastic Therapy market size was valued at US$ million in 2023. With growing demand in downstream market, the Anti-Neoplastic Therapy is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Anti-Neoplastic Therapy Market Size 2019-2030 2.1.2 Anti-Neoplastic Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Anti-Neoplastic Therapy Segment by Type 2.2.1 Chemotherapeutic Agents 2.2.2 Immunotherapeutic Agents 2.2.3 Personalized Medicine 2.3 Anti-Neoplastic Therapy Market Size by Type 2.3.1 Anti-Neoplastic Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Anti-Neoplastic Therapy Market Size Market Share by Type (2019-2024) 2.4 Anti-Neoplastic Therapy Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.4.3 Cancer Rehabilitation Centers 2.4.4 Ambulatory Surgical Centers 2.5 Anti-Neoplastic Therapy Market Size by Application 2.5.1 Anti-Neoplastic Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Anti-Neoplastic Therapy Market Size Market Share by Application (2019-2024) 3 Anti-Neoplastic Therapy Market Size by Player 3.1 Anti-Neoplastic Therapy Market Size Market Share by Players 3.1.1 Global Anti-Neoplastic Therapy Revenue by Players (2019-2024) 3.1.2 Global Anti-Neoplastic Therapy Revenue Market Share by Players (2019-2024) 3.2 Global Anti-Neoplastic Therapy Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Anti-Neoplastic Therapy by Regions 4.1 Anti-Neoplastic Therapy Market Size by Regions (2019-2024) 4.2 Americas Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.3 APAC Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.4 Europe Anti-Neoplastic Therapy Market Size Growth (2019-2024) 4.5 Middle East & Africa Anti-Neoplastic Therapy Market Size Growth (2019-2024) 5 Americas 5.1 Americas Anti-Neoplastic Therapy Market Size by Country (2019-2024) 5.2 Americas Anti-Neoplastic Therapy Market Size by Type (2019-2024) 5.3 Americas Anti-Neoplastic Therapy Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Anti-Neoplastic Therapy Market Size by Region (2019-2024) 6.2 APAC Anti-Neoplastic Therapy Market Size by Type (2019-2024) 6.3 APAC Anti-Neoplastic Therapy Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Anti-Neoplastic Therapy by Country (2019-2024) 7.2 Europe Anti-Neoplastic Therapy Market Size by Type (2019-2024) 7.3 Europe Anti-Neoplastic Therapy Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Anti-Neoplastic Therapy by Region (2019-2024) 8.2 Middle East & Africa Anti-Neoplastic Therapy Market Size by Type (2019-2024) 8.3 Middle East & Africa Anti-Neoplastic Therapy Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Anti-Neoplastic Therapy Market Forecast 10.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030) 10.1.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030) 10.1.2 Americas Anti-Neoplastic Therapy Forecast 10.1.3 APAC Anti-Neoplastic Therapy Forecast 10.1.4 Europe Anti-Neoplastic Therapy Forecast 10.1.5 Middle East & Africa Anti-Neoplastic Therapy Forecast 10.2 Americas Anti-Neoplastic Therapy Forecast by Country (2025-2030) 10.2.1 United States Anti-Neoplastic Therapy Market Forecast 10.2.2 Canada Anti-Neoplastic Therapy Market Forecast 10.2.3 Mexico Anti-Neoplastic Therapy Market Forecast 10.2.4 Brazil Anti-Neoplastic Therapy Market Forecast 10.3 APAC Anti-Neoplastic Therapy Forecast by Region (2025-2030) 10.3.1 China Anti-Neoplastic Therapy Market Forecast 10.3.2 Japan Anti-Neoplastic Therapy Market Forecast 10.3.3 Korea Anti-Neoplastic Therapy Market Forecast 10.3.4 Southeast Asia Anti-Neoplastic Therapy Market Forecast 10.3.5 India Anti-Neoplastic Therapy Market Forecast 10.3.6 Australia Anti-Neoplastic Therapy Market Forecast 10.4 Europe Anti-Neoplastic Therapy Forecast by Country (2025-2030) 10.4.1 Germany Anti-Neoplastic Therapy Market Forecast 10.4.2 France Anti-Neoplastic Therapy Market Forecast 10.4.3 UK Anti-Neoplastic Therapy Market Forecast 10.4.4 Italy Anti-Neoplastic Therapy Market Forecast 10.4.5 Russia Anti-Neoplastic Therapy Market Forecast 10.5 Middle East & Africa Anti-Neoplastic Therapy Forecast by Region (2025-2030) 10.5.1 Egypt Anti-Neoplastic Therapy Market Forecast 10.5.2 South Africa Anti-Neoplastic Therapy Market Forecast 10.5.3 Israel Anti-Neoplastic Therapy Market Forecast 10.5.4 Turkey Anti-Neoplastic Therapy Market Forecast 10.5.5 GCC Countries Anti-Neoplastic Therapy Market Forecast 10.6 Global Anti-Neoplastic Therapy Forecast by Type (2025-2030) 10.7 Global Anti-Neoplastic Therapy Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Amgen Inc. 11.1.1 Amgen Inc. Company Information 11.1.2 Amgen Inc. Anti-Neoplastic Therapy Product Offered 11.1.3 Amgen Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Amgen Inc. Main Business Overview 11.1.5 Amgen Inc. Latest Developments 11.2 AstraZeneca plc 11.2.1 AstraZeneca plc Company Information 11.2.2 AstraZeneca plc Anti-Neoplastic Therapy Product Offered 11.2.3 AstraZeneca plc Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 AstraZeneca plc Main Business Overview 11.2.5 AstraZeneca plc Latest Developments 11.3 Bayer AG 11.3.1 Bayer AG Company Information 11.3.2 Bayer AG Anti-Neoplastic Therapy Product Offered 11.3.3 Bayer AG Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Bayer AG Main Business Overview 11.3.5 Bayer AG Latest Developments 11.4 Johnson & Johnson 11.4.1 Johnson & Johnson Company Information 11.4.2 Johnson & Johnson Anti-Neoplastic Therapy Product Offered 11.4.3 Johnson & Johnson Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Johnson & Johnson Main Business Overview 11.4.5 Johnson & Johnson Latest Developments 11.5 Merck & Co., Inc. 11.5.1 Merck & Co., Inc. Company Information 11.5.2 Merck & Co., Inc. Anti-Neoplastic Therapy Product Offered 11.5.3 Merck & Co., Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Merck & Co., Inc. Main Business Overview 11.5.5 Merck & Co., Inc. Latest Developments 11.6 Pfizer Inc. 11.6.1 Pfizer Inc. Company Information 11.6.2 Pfizer Inc. Anti-Neoplastic Therapy Product Offered 11.6.3 Pfizer Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 Pfizer Inc. Main Business Overview 11.6.5 Pfizer Inc. Latest Developments 11.7 F. Hoffmann-La Roche Ltd. 11.7.1 F. Hoffmann-La Roche Ltd. Company Information 11.7.2 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Product Offered 11.7.3 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 F. Hoffmann-La Roche Ltd. Main Business Overview 11.7.5 F. Hoffmann-La Roche Ltd. Latest Developments 11.8 Eli Lilly and Company 11.8.1 Eli Lilly and Company Company Information 11.8.2 Eli Lilly and Company Anti-Neoplastic Therapy Product Offered 11.8.3 Eli Lilly and Company Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Eli Lilly and Company Main Business Overview 11.8.5 Eli Lilly and Company Latest Developments 11.9 Teva Pharmaceutical Industries Ltd. 11.9.1 Teva Pharmaceutical Industries Ltd. Company Information 11.9.2 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Product Offered 11.9.3 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 Teva Pharmaceutical Industries Ltd. Main Business Overview 11.9.5 Teva Pharmaceutical Industries Ltd. Latest Developments 11.10 Boehringer Ingelheim 11.10.1 Boehringer Ingelheim Company Information 11.10.2 Boehringer Ingelheim Anti-Neoplastic Therapy Product Offered 11.10.3 Boehringer Ingelheim Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.10.4 Boehringer Ingelheim Main Business Overview 11.10.5 Boehringer Ingelheim Latest Developments 11.11 Aspen Pharmacare Holdings Limited 11.11.1 Aspen Pharmacare Holdings Limited Company Information 11.11.2 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Product Offered 11.11.3 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.11.4 Aspen Pharmacare Holdings Limited Main Business Overview 11.11.5 Aspen Pharmacare Holdings Limited Latest Developments 11.12 AbbVie Inc. 11.12.1 AbbVie Inc. Company Information 11.12.2 AbbVie Inc. Anti-Neoplastic Therapy Product Offered 11.12.3 AbbVie Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024) 11.12.4 AbbVie Inc. Main Business Overview 11.12.5 AbbVie Inc. Latest Developments 12 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
LP Information社の医療分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|